Oddo BHF - Evotec AG ADS (EVTA) Evotec AG : Strong H1 2018 results with adj. EBITDA 12.5% above consensus

Report

Oddo BHF

Evotec AG : Strong H1 2018 results with adj. EBITDA 12.5% above consensus

>Both the Execute and Innovate segments contributed to a strong H1 2018 performance - Evotec posted very strong H1 2018 results today (09 Aug) with group revenue of â‚¬Â 173.8m (+67% yoy) beating market expectations by 8% (cons.: â‚¬Â 160.7m; Oddo BHFe: â‚¬Â 162.2m). The strong revenue performance was driven by i/ Aptuitâ€™s contribution; ii/ a strong base business; iii/ milestone payments, and iv/ the signing of new partnerships. The beat was even stronger on the group adj. EB...

09/08/2018 4 EN

Underlying

Evotec AG ADS

See profile

US30050E1055 Frankfurt Stock Exchange Germany

Provider

Oddo BHF

Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

See profile

Other Reports on these Companies

EQUITS GmbH

Bayer AG stoppt EVT-Hoffnungsträger „Eliapixant“ – Finanzierung für weiterhin gültigen „Actionplan 2025“ neu zu justieren

Sehr überraschend kommt am 04.02.22 die Entscheidung vom Partner Bayer AG, das in Phase 2a befindliche Projekt „Eliapixant“ (BAY 1817080) zu stoppen und das für EVT potentiell sehr profitable P2X3-Antagonisten-Programm zurückzugeben. Eine zügige Weiterverwertung erwarten wir- Stand heute - nicht. Wir passen die Pipelinebewertung und folglich den Zielkurs an. Das Geschäftsmodell wird u.E. kapitallastiger, nun dürfte die Ergebnisprognose für die kommenden Jahre sinken. Die Profitverbesserung durch den „Actionplan 2025“ sei lt. Unternehmen weiterhin gültig. Wir waren bereits im Nov. 21 vorsicht...

EUR 240.00

February 4, 2022 February 4, 2022 5 DE

EQUITS GmbH

Bayer AG stops EVT hopeful "Eliapixant" – Readjust financing for "Action Plan 2025", which is still valid

Very surprising on 04.02.22 comes the decision of the partner Bayer AG to stop the phase 2a project "Eliapixant" (BAY 1817080) to return the potentially very profitable P2X3 antagonist program for EVT. As of today, we do not expect rapid repartnering. We had estimated the project value at approx. € 1,500 m with a DCF value - we adjust the pipeline valuation and consequently the target price.

EUR 240.00

February 4, 2022 February 4, 2022 4 EN

EQUITS GmbH

Zweitnotiz an US-Nasdaq („EVO“) als ADS bringt $435 Mio. und wird „Actionplan 2025“ beschleunigen – Q3/21 erwartungstreu

Das aktuell hohe Interesse an Biotech-Investments in den USA hat EVT ab 08.11.21 mit einer Zweitnotierung (ADS/EVT-Aktien-Verhältnis 2 zu 1; ADS-Kurs: 21,75/ADS; 22,995 Mio. ADS-Scheine) an der US-Nasdaq genutzt und zusätzliches Kapital eingeworben. Wir passen die Schätzungen um die 13,3%ige Kapitalverwässerung an.

EUR 220.00

November 15, 2021 November 15, 2021 5 DE

ODDO BHF European Large Caps List : 4 entrées et 6 sorties pour refléter les changements de notre allocation sectorielle trimestrielle publiée ce jour

Depuis sa création (le 12 décembre dernier), notre liste de convictions ODDO BHF European Large Caps 2025 affiche une performance de 19%, ce qui correspond à une surperformance de 12% versus le Stoxx 600 qui progresse, lui, de 7% (dividendes inclus). Nous faisons entrer 4 nouvelles valeurs conformément à la nouvelle allocation sectorielle publiée ce jour dans notre trimestriel stratégie : Elia, Intesa Sanpaolo, Technip Energies, Voestalpine. 6 valeurs quittent la liste : Amadeus, Anheuser-Busch InBev, Inditex, Knorr-Bremse, RELX, Sanofi.

11h / 20m 11h / 20m 1 FR

Thomas Zlowodzki

Thomas Zlowodzki

ODDO BHF European Large Caps List: 4 additions and 6 removals to reflect the changes to our quarterly sector allocation published today

Since it was created on 12 December 2024, our ODDO BHF European Large Caps 2025 list has chalked up a performance of 19%, i.e. an outperformance of 12% vs the Stoxx 600 which has gained 7% (dividends included). We have added four new stocks in accordance with the new sector allocation published today in our quarterly: Elia, Intesa Sanpaolo, Technip Energies and Voestalpine. We have removed six stocks: Amadeus, Anheuser-Busch InBev, Inditex, Knorr-Bremse, RELX and Sanofi.

11h / 20m 11h / 20m 1 EN

Carole Braudeau

Carole Braudeau

Credit Morning 07/09/2025

Unicredit: EC said to reject Italian government use of golden power rules over the bid on Banco BPM and equity stake increased in Commerzbank|

18h / 56m 18h / 56m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Evotec AG : Strong H1 2018 results with adj. EBITDA 12.5% above consensus

Bayer AG stoppt EVT-Hoffnungsträger „Eliapixant“ – Finanzierung für weiterhin gültigen „Actionplan 2025“ neu zu justieren

Bayer AG stops EVT hopeful "Eliapixant" – Readjust financing for "Action Plan 2025", which is still valid

Zweitnotiz an US-Nasdaq („EVO“) als ADS bringt $435 Mio. und wird „Actionplan 2025“ beschleunigen – Q3/21 erwartungstreu

ODDO BHF European Large Caps List : 4 entrées et 6 sorties pour refléter les changements de notre allocation sectorielle trimestrielle publiée ce jour

ODDO BHF European Large Caps List: 4 additions and 6 removals to reflect the changes to our quarterly sector allocation published today

Credit Morning 07/09/2025

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe